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Ovarian Cancer
Castellon is a Spanish province situated in the east of Spain. As
many other Mediterranean countries the overall incidence of ovarian
cancer is low when compared with northern European countries
(approximately 8/100.000 habitants per year) [1]. At the same time the
five year relative survival is low when compared with EEUU and in the
Spanish province of Castellon is even lower than the rest of Spain [2].
Several prognostic factors for ovarian cancer have been studied and
reported in an attempt to increase tumor-free survival [2,3]. The most
important are International Federation of Gynecology and Obstetrics
(FIGO) stage, size of residual tumor after primary surgery and age at
diagnosis. As we know the 70-80% of ovarian cancers will be
diagnosed at advanced stage and the median age at diagnosis in our
patients is 65 years old. So the only parameter can be modified to
improve survival is our surgical technique. In our serie we are complete
convinced that our low survival and especially in advanced stages is
due to the residual tumor left after the cytoreductive surgery.
Is well known that in Spain we do not have a subespeciality in
Gynecology Oncology and the advanced ovarian cancer is a
challenging surgery if we attempt to perform a complete surgery.
Trying to improve the progression free interval and perhaps the overall
survival, a Multidisciplinary Unit of Abdominal Pelvic Oncology
Surgery (MUAPOS) was created at our institution in January 2013,
dedicating itself entirely to the treatment of advanced ovarian cancer
by incorporating extensive surgical techniques for cytoreduction of
advanced ovarian and peritoneal cancers. This multidisciplinary focus
of the technique used has reached an improvement in the percentage of
optimal achieved cytoreduction [4,5]. Nevertheless we have observed
that the type of surgery needed to achieve complete cytorreduction in
advanced ovarian cancer is aggressive and complex. For this reason,
specialist teams should be prepared to cope with a high rate of
complications, at least during their initial stages. Through the adequate
process of patient selection and the acquisition of a greater experience
in the cooperative treatment of advanced ovarian cancer, overall results
for this type of surgery should experience a rapid increase, in terms of
efficiency and safety.
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